|
Characteristic
|
ACPA-positive (n = 310)
|
ACPA-negative (n = 121)
|
Group difference
|
|---|
|
Female (number; %)
|
208 (67%)
|
89 (74%)
|
P = 0.1932
|
|
RF positive (number; %)
|
244 (79%)
|
47 (39%)
|
P <0.0012
|
|
Age (years)
|
54.0 (46.0, 64.0)
|
55.0 (47.0, 62.0)
|
P = 0.6611
|
|
Disease duration (months)
|
2.00 (0.00, 5.00)
|
1.00 (0.00, 4.00)
|
P = 0.1063
|
|
Larsen score
|
7.50 (2.50, 21.25)*
|
4.50 (1.00, 9.50)
|
P <0.0013
|
|
DAS28
|
5.72 (4.91, 6.73)
|
5.96 (4.92, 6.85)
|
P = 0.3051
|
|
HAQ
|
1.62 (1.00, 2.12)
|
1.62 (1.12, 2.12)
|
P = 0.5953
|
|
EuroQol
|
0.60 (0.15, 0.68)
|
0.58 (0.08, 0.68)
|
P = 0.5523
|
|
SF-36 PCS
|
28.68 (23.24, 35.95)
|
28.70 (22.90, 35.56)
|
P = 0.7133
|
|
SF-36 MCS
|
38.64 (27.65, 53.71)
|
35.87 (25.37, 52.95)
|
P = 0.2173
|
- All data are median interquartile range (IQR) unless otherwise stated; 1 = t-test; 2 = chi-squared test; 3 = Wilcoxon signed-rank test; *baseline Larsen scores missing in two ACPA-positive patients. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RF, rheumatoid factor.
